MEP60608A - INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkappaB KINASE - Google Patents

INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkappaB KINASE

Info

Publication number
MEP60608A
MEP60608A MEP-606/08A MEP60608A MEP60608A ME P60608 A MEP60608 A ME P60608A ME P60608 A MEP60608 A ME P60608A ME P60608 A MEP60608 A ME P60608A
Authority
ME
Montenegro
Prior art keywords
indole
modulating
benzimidazole derivatives
ikappab kinase
compounds
Prior art date
Application number
MEP-606/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Olaf Ritzeler
Gerhard Jaehne
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP60608A publication Critical patent/MEP60608A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
MEP-606/08A 2002-08-17 2003-08-05 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkappaB KINASE MEP60608A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10237722A DE10237722A1 (de) 2002-08-17 2002-08-17 Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
YU20050104A RS51902B (sr) 2002-08-17 2003-08-05 Derivati indola ili benzimidazola za modulaciju ikb-kinaze
PCT/EP2003/008629 WO2004022553A1 (fr) 2002-08-17 2003-08-05 DERIVES D'INDOLE OU DE BENZIMIDAZOLE POUR MODULER L'IλB KINASE

Publications (1)

Publication Number Publication Date
MEP60608A true MEP60608A (en) 2011-05-10

Family

ID=31968974

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-606/08A MEP60608A (en) 2002-08-17 2003-08-05 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkappaB KINASE

Country Status (43)

Country Link
US (2) US7285560B2 (fr)
EP (2) EP1530568B1 (fr)
JP (1) JP4504812B2 (fr)
KR (1) KR101162046B1 (fr)
CN (1) CN1314683C (fr)
AR (1) AR040975A1 (fr)
AT (2) ATE557018T1 (fr)
AU (1) AU2003263196B2 (fr)
BR (1) BR0313562A (fr)
CA (1) CA2498559C (fr)
CO (1) CO5690586A2 (fr)
CR (1) CR7668A (fr)
CY (2) CY1111692T1 (fr)
DE (2) DE10237722A1 (fr)
DK (2) DK2233483T3 (fr)
EC (1) ECSP055612A (fr)
ES (2) ES2387954T3 (fr)
HK (1) HK1079509A1 (fr)
HN (1) HN2003000249A (fr)
HR (1) HRP20050042B1 (fr)
IL (1) IL166785A0 (fr)
JO (1) JO2764B1 (fr)
MA (1) MA27382A1 (fr)
ME (1) MEP60608A (fr)
MX (1) MXPA05001314A (fr)
MY (1) MY140074A (fr)
NO (1) NO330981B1 (fr)
NZ (1) NZ538296A (fr)
OA (1) OA12908A (fr)
PA (1) PA8580501A1 (fr)
PE (1) PE20040893A1 (fr)
PL (1) PL374229A1 (fr)
PT (2) PT1530568E (fr)
RS (1) RS51902B (fr)
RU (1) RU2318820C2 (fr)
SI (2) SI1530568T1 (fr)
SV (1) SV2004001599A (fr)
TN (1) TNSN05045A1 (fr)
TW (1) TWI290552B (fr)
UA (1) UA78591C2 (fr)
UY (1) UY27941A1 (fr)
WO (1) WO2004022553A1 (fr)
ZA (1) ZA200500322B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
EA011009B1 (ru) 2003-01-14 2008-12-30 Арена Фармасьютикалз Инк. 1,2,3-тризамещённые арильные и гетероарильные производные в качестве модуляторов метаболизма и профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CA2566213A1 (fr) * 2004-05-12 2005-12-11 Aventis Pharmaceuticals Inc. 2-{[2-(2-methylamino-pyrimidine-4-yl)-1h-indole-5-carbonyle]-amine}-3-(phenylpyridine-2-yl-amine)-acide propionique substantiellement pur comme inhibiteur de kinase ikb
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
DOP2006000010A (es) * 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
WO2006076318A1 (fr) * 2005-01-12 2006-07-20 Aventis Pharmaceuticals Inc. Sel monopotassique d'un inhibiteur de i$g(k)b kinase
US20070142417A1 (en) * 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2613068A1 (fr) 2005-06-30 2007-01-11 Smithkline Beecham Corporation Indole carboxamides en tant qu'inhibiteurs d'ikk2
JP5203196B2 (ja) * 2005-08-04 2013-06-05 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのオキサゾロピリジン誘導体
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
KR20080052650A (ko) 2005-09-07 2008-06-11 라보라토리스 세로노 에스.에이. 자궁내막증 치료용 ｉｋｋ 저해제
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
KR20100092000A (ko) * 2007-11-01 2010-08-19 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 아미드 유도체
AU2008325148A1 (en) * 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
UA104447C2 (uk) 2008-12-19 2014-02-10 Сіртріз Фармасьютікалз, Інк. Тіазолопіридинові сполуки, що модулюють сиртуїн
RU2544010C2 (ru) * 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
AU2010288523A1 (en) 2009-08-26 2012-03-15 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2528894A1 (fr) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Procédés de préparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétique et de ses sels
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011134140A1 (fr) 2010-04-27 2011-11-03 Hutchison Medipharma Limited Pyrimidinylindoles
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011288533A1 (en) 2010-08-12 2013-02-28 Sanofi Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
TW201242962A (en) * 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
HUE037645T2 (hu) * 2011-07-27 2018-09-28 Astrazeneca Ab Rák kezelésére alkalmas 2.(2,4,5-helyettesített-anilino)pirimidin származékok mint EGFR modulátorok
JP6035334B2 (ja) 2011-08-25 2016-11-30 セント ジュード チルドレンズ リサーチ ホスピタル 抗マラリア療法のための置換２−アルキル−１−オキソ−ｎ−フェニル−３−ヘテロアリール−１，２，３，４−テトラヒドロイソキノリン−４−カルボキサミド
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
PL2787998T3 (pl) * 2011-12-06 2017-04-28 Sanofi Formy krystaliczne [(S)-1-karbamoilo-2-(fenylopirymidyn-2-yloamino) etylo]-amidu kwasu 2-(2-metyloaminopirymidyn-4-ylo)-1H-indolo 5-karboksylowego
EA202092034A3 (ru) * 2012-01-27 2021-02-26 Астразенека Аб Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
KR101493877B1 (ko) 2013-03-29 2015-02-16 농업회사법인 주식회사 생명의나무 스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물
EP3184095A1 (fr) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Unitées d'administration comprennante une polymorphe 1 de 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
EP2905282A1 (fr) * 2014-02-05 2015-08-12 AXXAM S.p.A. Thiazole ou oxazole substituée en tant qu'antagonistes du récepteur P2X7
CA2951972A1 (fr) * 2014-07-03 2016-01-07 Sanofi Acide 2-(2-methylamino-pyrimidin-4-yl)-1 h-indole-5-carboxylique [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide utilisable dans le traitement de la douleur associee a l'arthrose
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3939965A1 (fr) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique pour une utilisation dans des troubles associés au récepteur de s1p1
EP3290416A1 (fr) * 2016-08-31 2018-03-07 AXXAM S.p.A. Dérivés de n-[2-(4-phénoxypipéridin-1-yl)-2-(1,3-thiazol-5-yl)éthyl]benzamide et n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)éthyl]benzamide substitués et leur utilisation en tant qu'antagoniste du récepteur p2x7
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法
CN108299302A (zh) * 2017-01-11 2018-07-20 西南科技大学 一种制备3-乙酰基吡唑的新方法
EP3582772A1 (fr) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN115052860B (zh) * 2020-01-30 2024-06-21 艾尼莫生物科技公司 胶原蛋白1翻译抑制剂和其使用方法
CN115974849B (zh) * 2022-12-28 2024-06-21 中国药科大学 一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2144763A1 (fr) 1992-10-14 1994-04-28 George D. Hartman Antagonistes des recepteurs du fibrinogene
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
IT1275433B (it) * 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
RU2261248C2 (ru) 1999-06-23 2005-09-27 Авентис Фарма Дойчланд Гмбх Замещенные бензимидазолы и лекарственное средство на их основе
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
CZ20032287A3 (cs) 2001-02-01 2004-02-18 Bristol-Myers Squibb Company Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7462638B2 (en) * 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7046741B2 (en) * 2004-04-16 2006-05-16 Data Flow Technologies, Inc. Single and multiple sinewave modulation and demodulation techniques, apparatus, and communications systems

Also Published As

Publication number Publication date
NZ538296A (en) 2007-03-30
CA2498559A1 (fr) 2004-03-18
US8778955B2 (en) 2014-07-15
EP2233483B1 (fr) 2012-05-09
PE20040893A1 (es) 2004-12-21
US20070244139A1 (en) 2007-10-18
KR101162046B1 (ko) 2012-07-04
RU2318820C2 (ru) 2008-03-10
HK1079509A1 (en) 2006-04-07
DE50313372D1 (de) 2011-02-10
HRP20050042B1 (hr) 2013-09-30
SV2004001599A (es) 2004-02-26
PT2233483E (pt) 2012-07-20
ZA200500322B (en) 2006-07-26
CN1675196A (zh) 2005-09-28
ATE493402T1 (de) 2011-01-15
EP1530568A1 (fr) 2005-05-18
EP1530568B1 (fr) 2010-12-29
WO2004022553A1 (fr) 2004-03-18
TW200418832A (en) 2004-10-01
ATE557018T1 (de) 2012-05-15
OA12908A (en) 2006-10-13
MY140074A (en) 2009-11-30
PA8580501A1 (es) 2004-04-23
CR7668A (es) 2009-03-11
AU2003263196B2 (en) 2009-01-22
US7285560B2 (en) 2007-10-23
AR040975A1 (es) 2005-04-27
TWI290552B (en) 2007-12-01
CY1112991T1 (el) 2016-04-13
CY1111692T1 (el) 2015-10-07
RU2005107418A (ru) 2005-08-27
ECSP055612A (es) 2005-04-18
MA27382A1 (fr) 2005-06-01
SI2233483T1 (sl) 2012-08-31
ES2387954T3 (es) 2012-10-04
AU2003263196A1 (en) 2004-03-29
CO5690586A2 (es) 2006-10-31
JP2005539054A (ja) 2005-12-22
CN1314683C (zh) 2007-05-09
RS20050104A (en) 2007-06-04
UY27941A1 (es) 2004-03-31
PL374229A1 (en) 2005-10-03
RS51902B (sr) 2012-02-29
US20050197353A1 (en) 2005-09-08
DE10237722A1 (de) 2004-08-19
JO2764B1 (en) 2014-03-15
KR20050058338A (ko) 2005-06-16
HRP20050042A2 (en) 2006-03-31
IL166785A0 (en) 2006-01-15
NO330981B1 (no) 2011-08-29
EP2233483A1 (fr) 2010-09-29
CA2498559C (fr) 2012-01-24
DK2233483T3 (da) 2012-08-20
DK1530568T3 (da) 2011-04-18
ES2358795T3 (es) 2011-05-13
JP4504812B2 (ja) 2010-07-14
UA78591C2 (en) 2007-04-10
PT1530568E (pt) 2011-02-23
BR0313562A (pt) 2006-06-13
SI1530568T1 (sl) 2011-05-31
HN2003000249A (es) 2008-08-06
MXPA05001314A (es) 2005-04-28
NO20051337L (no) 2005-05-03
TNSN05045A1 (en) 2007-05-14

Similar Documents

Publication Publication Date Title
MEP60608A (en) INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkappaB KINASE
ME00434B (fr) Indols substitues pour moduler l'activite du facteur de transcription nfkb
MEP56108A (en) Substituted benzimidazole
HRP20050041B1 (hr) UPOTREBA INHIBITORA IκB KINAZE U TERAPIJI BOLOVA
HRP20050059B8 (hr) Novi inhibitori kinaza
ATE281451T1 (de) Imidazolderivate und deren verwendung als raf kinase inhibitoren
NO20045589L (no) Nye forbindelser
NO20052796L (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
ME00415B (me) Pirol supstituisani 2-indol protein kinazni inhibitori
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
NO20044763L (no) 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
NO20073465L (no) Benzotiazol-derivater
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
EA200500392A1 (ru) Производные пиримидина и их применение в качестве модуляторов св2
CO5700775A2 (es) Nuevos derivados triciclicos como antagonistas de ltd4
ATE407120T1 (de) 3-((hetero)arylsulfonyl)-8- ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
MXPA04003087A (es) Derivados de cromano como ligados de 5-hidroxitriptamina-6.
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
NO20043952L (no) Benzofuran- og benzotiofenderivater som er nyttige ved behandling av hyperproliferative forstyrrelser
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
ATE432275T1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
BR0305708A (pt) Derivados de benzimidazol para o tratamento de disfunção sexual